<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062902" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of small intestine cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq">Small Intestine Cancer (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000038736">small intestine cancer</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Small Intestine Cancer Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Small Intestine Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038736">small intestine cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Small Intestine Cancer</Title><SummarySection id="_138"><Title>Incidence and Mortality</Title><Para id="_103">Estimated new cases and deaths from small intestine cancer in the United States in 2015:<Reference refidx="1"/></Para><ItemizedList id="_104" Style="bullet"><ListItem>New cases: 9,410.</ListItem><ListItem>Deaths: 1,260.</ListItem></ItemizedList></SummarySection><Para id="_2">Adenocarcinoma, lymphoma, sarcoma, and carcinoid tumors
account for the majority of small intestine malignancies, which, as a whole,
account for only 1% to 2% of all gastrointestinal malignancies.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>    </Para><SummarySection id="_151"><Title>Follow-up and Survivorship</Title><Para id="_152">As in
other gastrointestinal malignancies, the predominant modality of treatment is
surgery when resection is possible, and cure relates to the ability to
completely resect the cancer.  The overall 5-year survival rate for resectable
adenocarcinoma is only 20%.  The 5-year survival rate for resectable
leiomyosarcoma, the most common primary sarcoma of the small intestine, is
approximately 50%.</Para><Para id="_154">Carcinoid tumors of the small intestine are covered
elsewhere as a separate cancer entity. (Refer to the PDQ summary on
<SummaryRef href="CDR0000062893" url="/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq">Gastrointestinal Carcinoid Tumor Treatment</SummaryRef> for more information.)</Para></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <ExternalRef xref="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</ExternalRef>. Last accessed April 1, 2015.</Citation><Citation idx="2">Zureikat AH, Heller MT, Zeh HJ III: Cancer of the small intestine. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 1048-59.</Citation><Citation idx="3" PMID="1548877" MedlineID="92194732">Serour F, Dona G, Birkenfeld S, et al.: Primary neoplasms of the small bowel. J Surg Oncol 49 (1): 29-34, 1992.</Citation><Citation idx="4" PMID="8131869" MedlineID="94178391">Matsuo S, Eto T, Tsunoda T, et al.: Small bowel tumors: an analysis of tumor-like lesions, benign and malignant neoplasms. Eur J Surg Oncol 20 (1): 47-51, 1994.</Citation><Citation idx="5" PMID="8921448" MedlineID="97079737">Chow JS, Chen CC, Ahsan H, et al.: A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol 25 (4): 722-8, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_3"><SectMetaData><SpecificDiagnosis ref="CDR0000038736">small intestine cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Small Intestine Cancer</Title><Para id="_4">Tumors that occur in the small intestine include the following:</Para><ItemizedList id="_5" Style="bullet" Compact="No"><ListItem>Adenocarcinoma (majority of cases).
</ListItem>
<ListItem>Lymphoma (uncommon),  which is  usually of the non-Hodgkin type. (Refer to the PDQ summary on <SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef> for more information.)</ListItem>
<ListItem>Sarcoma (most commonly leiomyosarcoma and more rarely angiosarcoma or
liposarcoma).
</ListItem>
<ListItem>Carcinoid. (Refer to the PDQ summary on <SummaryRef href="CDR0000062893" url="/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq">Gastrointestinal Carcinoid Tumor
Treatment</SummaryRef> for more information.)</ListItem>
<ListItem>Gastrointestinal stromal tumors. (Refer to the PDQ summary on <SummaryRef href="CDR0000639481" url="/types/soft-tissue-sarcoma/hp/gist-treatment-pdq">Gastrointestinal Stromal Tumors Treatment</SummaryRef> for more information.)</ListItem>
</ItemizedList><Para id="_6">Approximately 25% to 50% of the primary malignant tumors in the small intestine are adenocarcinomas, and most occur in the duodenum.<Reference refidx="1"/> Small intestine carcinomas may occur synchronously or metachronously at
multiple sites.
</Para><Para id="_7">Leiomyosarcomas occur most often in the ileum.
</Para><Para id="_8">Some 20% of malignant lesions of the small intestine are carcinoid tumors,
which occur more frequently in the ileum than in the duodenum or jejunum and
may be multiple.
</Para><Para id="_9">It is uncommon to find malignant lymphoma as a solitary small intestine lesion.
</Para><ReferenceSection><Citation idx="1">Small intestine. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 127-32.</Citation></ReferenceSection></SummarySection><SummarySection id="_10"><SectMetaData><SpecificDiagnosis ref="CDR0000038736">small intestine cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Small Intestine Cancer</Title><Para id="_11">The treatment sections of this summary are organized according to
histopathologic type rather than stage.
</Para><SummarySection id="_133"><Title>Definitions of TNM</Title><Para id="_134">The American Joint Committee on Cancer (AJCC) has designated staging by TNM
classification to define small intestine cancer.<Reference refidx="1"/></Para><Table id="_127"><Title>Table 1.  Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.24%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.75%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small intestine. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 127-32.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>The nonperitonealized perimuscular tissue is, for jejunum and ileum, part of the mesentery and, for duodenum in areas where serosa is lacking, part of the interface with the pancreas.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>Tis</entry><entry>Carcinoma <Emphasis>in situ</Emphasis>.</entry></Row><Row><entry>T1a</entry><entry>Tumor invades lamina propria.</entry></Row><Row><entry>T1b</entry><entry>Tumor invades submucosa.<Superscript>b</Superscript></entry></Row><Row><entry>T2</entry><entry>Tumor invades muscularis propria.</entry></Row><Row><entry>T3</entry><entry>Tumor invades through the muscularis propria into the subserosa or into the nonperitonealized perimuscular tissue (mesentery or retroperitoneum) with extension ≤2 cm.<Superscript>b</Superscript></entry></Row><Row><entry>T4</entry><entry>Tumor perforates the visceral peritoneum or directly invades other organs or structures (includes other loops of small intestine, mesentery, or retroperitoneum &gt;2 cm, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct).</entry></Row></TBody></TGroup></Table><Table id="_128"><Title>Table 2.  Regional Lymph Nodes (N)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.83%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.16%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small intestine. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 127-32.</entry></Row></TFoot><TBody><Row><entry>NX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>N0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>N1</entry><entry>Metastasis in 1–3 regional lymph nodes.</entry></Row><Row><entry>N2</entry><entry>Metastases in ≥4 regional lymph nodes.</entry></Row></TBody></TGroup></Table><Table id="_129"><Title>Table 3.  Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.51%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.48%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small intestine. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 127-32.</entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_130"><Title>Table 4.  Anatomic Stage/Prognostic Groups<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Small intestine. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 127-32.</entry></Row></TFoot><TBody><Row><entry>0</entry><entry>Tis</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry MoreRows="1"> I</entry><entry>T1</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry> IIA</entry><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IIB</entry><entry>T4</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry> IIIA</entry><entry>Any T</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry> IIIB</entry><entry>Any T</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry> IV</entry><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1">Small intestine. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 127-32.</Citation></ReferenceSection></SummarySection><SummarySection id="_36"><SectMetaData><SpecificDiagnosis ref="CDR0000038744">small intestine adenocarcinoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Small Intestine Adenocarcinoma</Title><Para id="_37"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_83" Style="Arabic"><ListItem>For resectable primary disease:<ItemizedList id="_39" Style="bullet"><ListItem>Radical surgical resection.<Reference refidx="1"/><Reference refidx="2"/>
</ListItem>
</ItemizedList></ListItem><ListItem>For unresectable primary disease:<ItemizedList id="_41" Style="bullet"><ListItem>Surgical bypass of obstructing lesion.
</ListItem>
<ListItem>Palliative radiation therapy.
</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_42"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><OrderedList id="_84" Style="Arabic" Compact="No"><ListItem>For unresectable primary disease:
<ItemizedList id="_44" Style="bullet"><ListItem>Clinical trials evaluating methods to improve local control, such as the
use of radiation therapy with radiosensitizers with or without systemic
chemotherapy.
</ListItem>
</ItemizedList></ListItem><ListItem>For unresectable metastatic disease:<ItemizedList id="_47" Style="bullet"><ListItem>Clinical trials evaluating the value of new anticancer drugs and
biologicals (phase I and phase II studies).
</ListItem>
</ItemizedList></ListItem></OrderedList><SummarySection id="_TrialSearch_36_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_36_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38744&amp;tt=1&amp;format=2&amp;cn=1">small intestine adenocarcinoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_36_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8696551" MedlineID="96326510">Rose DM, Hochwald SN, Klimstra DS, et al.: Primary duodenal adenocarcinoma: a ten-year experience with 79 patients. J Am Coll Surg 183 (2): 89-96, 1996.</Citation><Citation idx="2" PMID="10651347">North JH, Pack MS: Malignant tumors of the small intestine: a review of 144 cases. Am Surg 66 (1): 46-51, 2000.</Citation></ReferenceSection></SummarySection><SummarySection id="_60"><SectMetaData><SpecificDiagnosis ref="CDR0000038746">small intestine leiomyosarcoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Small Intestine Leiomyosarcoma</Title><Para id="_61"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_86" Style="Arabic"><ListItem>For resectable primary disease:
<ItemizedList id="_63" Style="bullet"><ListItem>Radical surgical resection.
</ListItem>
</ItemizedList></ListItem><ListItem> For unresectable primary disease:<ItemizedList id="_65" Style="bullet"><ListItem>Surgical bypass of obstructing lesion and radiation therapy.
</ListItem>
</ItemizedList></ListItem><ListItem>For unresectable metastatic disease:<ItemizedList id="_67" Style="bullet"><ListItem>Palliative surgery.
</ListItem>
<ListItem>Palliative radiation therapy.
</ListItem>
<ListItem>Palliative chemotherapy.
</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_68"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_87" Style="bullet"><ListItem>For unresectable primary or metastatic disease:
<ItemizedList id="_70" Style="dash"><ListItem>Clinical trials evaluating the value of new anticancer drugs and
biologicals.
</ListItem>
</ItemizedList></ListItem></ItemizedList><SummarySection id="_TrialSearch_60_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_60_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38746&amp;tt=1&amp;format=2&amp;cn=1">small intestine leiomyosarcoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_60_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection></SummarySection><SummarySection id="_72"><SectMetaData><SpecificDiagnosis ref="CDR0000038757">recurrent small intestine cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Recurrent Small Intestine Cancer</Title><Para id="_73"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_88" Style="Arabic" Compact="No"><ListItem>For metastatic adenocarcinoma or leiomyosarcoma:
<ItemizedList id="_75" Style="bullet"><ListItem>No standard effective chemotherapy exists for patients with recurrent metastatic
adenocarcinoma or leiomyosarcoma of the small intestine.  These types of  patients
should be considered candidates for clinical trials evaluating the use of new
anticancer drugs or biologicals in phase I and phase II trials.
</ListItem>
</ItemizedList></ListItem><ListItem> For locally recurrent disease:<ItemizedList id="_81" Style="bullet"><ListItem>Surgery.
</ListItem>
<ListItem>Palliative radiation therapy.
</ListItem>
<ListItem>Palliative chemotherapy.
</ListItem>
<ListItem>Clinical trials evaluating ways of improving local control, such as the use
of radiation therapy with radiosensitizers with or without systemic
chemotherapy.
</ListItem>
</ItemizedList>
</ListItem></OrderedList><SummarySection id="_TrialSearch_72_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_72_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38757&amp;tt=1&amp;format=2&amp;cn=1">recurrent small intestine cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_72_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection></SummarySection><SummarySection id="_100"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (04/28/2015)</Title><Para id="_101">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_160"><Strong><SummaryRef href="CDR0000062902#_1" url="/types/small-intestine/hp/small-intestine-treatment-pdq">General Information About Small Intestine Cancer </SummaryRef></Strong></Para><Para id="_161">Updated <SummaryRef href="CDR0000062902#_103" url="/types/small-intestine/hp/small-intestine-treatment-pdq">statistics</SummaryRef> with estimated new cases and deaths for 2015 (cited American Cancer Society as reference 1).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062902#_AboutThis_1" url="http://www.cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of small intestine cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Small Intestine Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Jason E. Faris, MD (Massachusetts General Hospital)</ListItem><ListItem>Jennifer Wo, MD (Massachusetts General Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Small Intestine Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq">http://www.cancer.gov/types/small-intestine/hp/small-intestine-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-04-28</DateLastModified></Summary>
